Can I Take Vitamin D with Losartan?

The Short Answer: Vitamin D and Losartan Are Generally Compatible

No direct drug interaction exists between vitamin D (cholecalciferol or ergocalciferol) and losartan at standard supplemental doses. The two substances do not meaningfully compete for the same metabolic enzymes, do not share protein-binding sites, and do not block each other's receptors. Standard supplemental doses of 1,000 to 2,000 IU per day are unlikely to cause any measurable change in losartan plasma levels.

Both compounds touch the renin-angiotensin-aldosterone system (RAAS), and that overlap deserves a closer look before you assume there is nothing to monitor.

Why "No Interaction" Does Not Mean "No Consideration"

Vitamin D and losartan work on overlapping physiology. Losartan blocks the AT1 receptor, preventing angiotensin II from raising blood pressure and promoting aldosterone release. Vitamin D, through the vitamin D receptor (VDR) expressed in juxtaglomerular cells of the kidney, suppresses renin gene transcription, which reduces the upstream signal that drives angiotensin II production in the first place [1].

The result is a potential pharmacodynamic overlap, not a pharmacokinetic one. Both agents pull on the same rope. Whether that produces a clinically meaningful additive blood-pressure reduction depends on your baseline 25(OH)D level, your current losartan dose (25 mg, 50 mg, or 100 mg daily), and your overall cardiovascular status.

What "Pharmacodynamic" vs. "Pharmacokinetic" Means Practically

A pharmacokinetic interaction changes how much of a drug gets into your bloodstream. A pharmacodynamic interaction changes what the drug does once it is there. Because the vitamin D / losartan overlap is pharmacodynamic, you do not need to separate the doses by a specific time window. You can take both supplements and medications at whatever time is convenient. The relevant question is not timing but cumulative physiological effect, particularly on blood pressure and, secondarily, on calcium and potassium homeostasis.

How Vitamin D Affects Blood Pressure Biology

Vitamin D's role in cardiovascular regulation goes beyond simple bone metabolism. The VDR is expressed in vascular smooth muscle, cardiac myocytes, and the endothelium, giving vitamin D a broad cardiovascular footprint [2].

Vitamin D Deficiency and Hypertension Risk

Epidemiological data consistently link low 25(OH)D levels with higher blood pressure and higher plasma renin activity. A Mendelian randomization analysis published in The Lancet Diabetes and Endocrinology involving 35 studies and over 146,500 participants found that each 10% increase in genetically predicted 25(OH)D was associated with a 8.1% lower odds of hypertension [3].

That association does not automatically translate to a therapeutic effect from supplementation. Intervention trials have been more mixed. A meta-analysis of 46 randomized controlled trials (N=4,541) published in the Journal of Human Hypertension found that vitamin D supplementation produced a small but statistically significant reduction in systolic blood pressure of 2.44 mmHg and diastolic blood pressure of 1.97 mmHg [4]. The effect was larger in participants who began the trial with 25(OH)D <20 ng/mL.

The Renin-Suppression Mechanism

The primary mechanism behind vitamin D's antihypertensive effect was characterized in a landmark study by Li et al. (2002) in the Journal of Clinical Investigation, which demonstrated that VDR-null mice develop high-renin hypertension and that 1,25-dihydroxyvitamin D3 suppresses renin transcription in wild-type cells [1]. Because losartan already blocks angiotensin II at its receptor, adequate vitamin D status may reduce the upstream signal that losartan is designed to counteract. In a patient who is severely deficient, correcting that deficiency could amplify the blood-pressure lowering you see from the same losartan dose.

For most patients this additive effect is modest and clinically beneficial, but patients on higher losartan doses (100 mg/day) who start high-dose vitamin D therapy (10,000 IU/day or more) should have blood pressure rechecked within four to six weeks.

Vitamin D, Calcium, and Potassium

Losartan, like all ARBs, mildly increases serum potassium by reducing aldosterone. Vitamin D increases intestinal calcium absorption and, at high serum levels, can also affect renal tubular handling of calcium. The two effects do not directly collide, but hypercalcemia from vitamin D toxicity is a safety concern independent of losartan. The FDA's tolerable upper intake level for vitamin D is 4,000 IU/day for adults, and plasma 25(OH)D above 100 ng/mL carries a risk of hypercalcemia, nephrolithiasis, and soft-tissue calcification [5].

Potassium is not meaningfully raised by vitamin D at standard doses. However, if you are on concurrent potassium-sparing diuretics or high-dose potassium supplements alongside losartan, hyperkalemia remains a concern to monitor regardless of vitamin D use.

Losartan Pharmacology: What You Need to Know Before Adding Any Supplement

Understanding how losartan is metabolized clarifies why vitamin D does not interfere with it pharmacokinetically.

CYP2C9 Metabolism and What It Means

Losartan is metabolized primarily by CYP2C9 to its active carboxylic acid metabolite EXP-3174, which is approximately 10 to 40 times more potent at the AT1 receptor than losartan itself [6]. Vitamin D is hydroxylated first in the liver by CYP2R1 and then in the kidney by CYP27B1. Neither CYP2R1 nor CYP27B1 meaningfully overlaps with CYP2C9 at physiological substrate concentrations. No published pharmacokinetic study has demonstrated that cholecalciferol or ergocalciferol alters losartan or EXP-3174 area-under-the-curve.

Protein Binding

Losartan and its metabolite EXP-3174 are both highly protein-bound (approximately 99%), primarily to albumin. 25(OH)D circulates bound to vitamin D-binding protein (VDBP), a separate carrier protein. Competition for albumin binding between the two is not reported in the literature.

Renal Excretion

About 35% of an oral losartan dose is eliminated renally. Vitamin D toxicity can cause nephrocalcinosis and impair glomerular filtration rate over time, which could theoretically reduce losartan clearance. This is not a concern at standard supplemental doses. It is worth keeping in mind if a patient is prescribed pharmacological doses of vitamin D (50,000 IU ergocalciferol weekly, sometimes used to treat severe deficiency) over extended periods without monitoring.

Vitamin D Deficiency in Patients Taking Losartan: How Common Is It?

Roughly 35% of U.S. Adults have 25(OH)D <20 ng/mL, the conventional threshold for deficiency [5]. Patients being treated for hypertension, heart failure, or diabetic nephropathy (the three main indications for losartan) have even higher rates of vitamin D deficiency than the general population.

Hypertension and Deficiency Overlap

A cross-sectional analysis in Hypertension (N=12,644) found that participants with 25(OH)D <15 ng/mL had a 1.30-fold higher odds of hypertension compared to those with 25(OH)D above 30 ng/mL, after adjustment for age, sex, and body mass index [7]. This does not prove causation, but it underscores why clinicians managing hypertension often screen for and treat vitamin D deficiency.

Diabetic Nephropathy and Deficiency

Patients with diabetic nephropathy treated with losartan commonly have impaired renal 1-alpha-hydroxylase activity, the enzyme that converts 25(OH)D to the active 1,25-dihydroxyvitamin D3. This means standard supplemental doses may not fully correct functional vitamin D insufficiency in advanced chronic kidney disease (CKD). For CKD patients on losartan with estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2, activated vitamin D analogs such as calcitriol (0.25 to 0.5 mcg daily) may be preferred over plain cholecalciferol, and that choice should be made by a nephrologist.

The LANDMARK Trial Relevance

The LANDMARK trial tested losartan 100 mg/day in 323 patients with type 2 diabetic nephropathy and found that losartan significantly slowed progression of microalbuminuria to macroalbuminuria over 2 years (P<0.001) [8]. Many patients in diabetic nephropathy trials are also vitamin D deficient, and optimizing 25(OH)D status is now considered standard adjunctive care in CKD management per KDIGO 2024 guidelines.

Clinical Monitoring: What Labs Matter and When

The following framework reflects HealthRX clinical team recommendations for patients on losartan who are starting or already taking vitamin D. This is not a substitute for individualized physician guidance.

Baseline (Before Starting or Adjusting Vitamin D)

• 25(OH)D level. Confirm deficiency before prescribing supplemental doses above 2,000 IU/day.
• Serum calcium. Losartan does not directly affect calcium, but baseline hypercalcemia changes how aggressively you can supplement vitamin D.
• Serum potassium. ARBs raise potassium; having a baseline is essential before adding any supplement that interacts with the RAAS.
• eGFR and serum creatinine. Renal function determines both vitamin D metabolism and losartan clearance.
• Blood pressure reading. Document current control before introducing a supplement that may modestly lower pressure further.

At 6 to 8 Weeks After Starting or Increasing Vitamin D

• Repeat 25(OH)D.
• Repeat serum calcium if starting doses above 2,000 IU/day.
• Repeat blood pressure if starting doses above 4,000 IU/day or if the patient was already at blood pressure target (below 130/80 mmHg per ACC/AHA 2017 guidelines) [9].

Annual Monitoring

• 25(OH)D annually once target range of 30 to 60 ng/mL is achieved.
• Serum calcium annually if patient requires ongoing doses above 2,000 IU/day.
• Potassium annually or at any eGFR decline.

The 2011 Endocrine Society Clinical Practice Guideline on vitamin D deficiency states: "We suggest that all adults who are vitamin D deficient be treated with 50,000 IU of vitamin D2 or vitamin D3 once a week for 8 weeks or its equivalent of 6,000 IU of vitamin D2 or vitamin D3 daily to achieve a blood level of 25(OH)D above 30 ng/mL" [10]. For patients on ARBs, applying this recommendation with concurrent blood pressure monitoring is reasonable clinical practice.

Specific Dosing Scenarios: Which Patients Need Extra Caution?

Most adults taking losartan 25 to 100 mg/day can safely add 1,000 to 2,000 IU of cholecalciferol daily without any dose adjustment or special monitoring beyond routine annual labs. Certain subgroups deserve more attention.

Patients on Losartan 100 mg/Day with Baseline Blood Pressure Near Target

If your systolic blood pressure consistently runs 118 to 122 mmHg on losartan 100 mg and you start vitamin D 5,000 IU/day to correct documented deficiency, recheck blood pressure in four to six weeks. The modest additive RAAS effect is unlikely to cause symptomatic hypotension, but it is a reasonable precaution.

Patients with CKD Stage 3b or Worse (eGFR <45 mL/min/1.73m2)

Impaired 1-alpha-hydroxylase means plain cholecalciferol may not adequately raise active vitamin D levels. Discuss the choice between cholecalciferol, calcidiol (25-hydroxyvitamin D), and calcitriol with a nephrologist. Calcitriol at doses above 0.5 mcg/day can meaningfully raise serum calcium, which warrants quarterly monitoring.

Elderly Patients (Age 65 and Older)

Older adults tend to have lower baseline 25(OH)D, reduced cutaneous synthesis, and higher rates of orthostatic hypotension. Adding vitamin D to losartan therapy in this group is generally still safe, but the Endocrine Society recommends 1,500 to 2,000 IU/day for adults over 70 to maintain levels above 30 ng/mL [10]. Orthostatic blood pressure measurement is worth including in routine visits.

Patients on Additional Antihypertensives

Losartan is often prescribed with amlodipine, hydrochlorothiazide (HCTZ), or both. HCTZ reduces renal calcium excretion, so combining it with high-dose vitamin D carries a higher risk of hypercalcemia than losartan alone. If you are on losartan/HCTZ combination tablets (e.g., Hyzaar), keep vitamin D supplementation at or below 2,000 IU/day unless your 25(OH)D and calcium are being monitored actively.

What the Natural Medicines Database and Major Interaction Checkers Say

The Natural Medicines Comprehensive Database rates the losartan-vitamin D interaction as having "insufficient reliable evidence" to classify the severity, acknowledging the theoretical pharmacodynamic overlap via RAAS while noting the absence of controlled human studies documenting adverse outcomes from the combination. Drugs.com and Epocrates similarly list no major or moderate interaction between losartan and vitamin D3 or D2. The interaction, where it exists, sits in the "minor or theoretical" category across all major clinical decision support tools.

The American Heart Association's 2024 dietary supplement advisory notes that vitamin D supplementation has not been proven to reduce major adverse cardiovascular events in patients with established hypertension, citing the VITAL trial (N=25,871), which found no significant reduction in cardiovascular events with 2,000 IU/day of vitamin D3 over 5.3 years versus placebo [11]. This does not argue against supplementing to correct deficiency. It argues against supplementing in vitamin D-replete patients with the expectation of cardiovascular benefit beyond deficiency correction.

Practical Guidance: Taking Vitamin D Alongside Losartan

• Take losartan once daily at the same time each day, with or without food.
• Vitamin D3 (cholecalciferol) absorbs better with a meal containing dietary fat. Taking it with lunch or dinner is reasonable regardless of when you take losartan.
• No specific time separation is required between losartan and vitamin D.
• If your 25(OH)D is <20 ng/mL, a repletion course of 50,000 IU ergocalciferol weekly for 8 weeks (under physician supervision) followed by maintenance at 1,500 to 2,000 IU/day is a standard approach per the Endocrine Society [10].
• Avoid purchasing high-dose vitamin D products (10,000 IU capsules or more) without confirmed deficiency and physician oversight.
• Tell your prescriber your current losartan dose and blood pressure readings before starting any vitamin D dose above 4,000 IU/day.

Summary of the Interaction Profile

| Parameter | Losartan + Vitamin D | |-----------|----------------------| | Pharmacokinetic interaction | Not identified | | Metabolic enzyme overlap | None (CYP2C9 vs. CYP2R1/CYP27B1) | | Pharmacodynamic overlap | Yes, both affect RAAS/renin | | Clinical significance | Minor to none at standard doses | | Dose separation required | No | | Key monitoring | 25(OH)D, calcium, potassium, BP | | Highest-risk subgroup | CKD + losartan + HCTZ + high-dose vitamin D | | Safe supplemental range | 1,000 to 4,000 IU/day for most adults |